China Pharma Holdings, Inc. CPHI
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
China Pharma Holdings, Inc. (CPHI) is a healthcare company listed in the US with a market value of about $22M. In the twelve months to June 30, 2026 it had revenue of $4M and net income of -$4M, a net margin of -114.3%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 250.6, 5-year revenue growth of -18% a year, a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.
About China Pharma
China Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $22M in 2014 to $4M in 2025, a decline of about 14.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3982% over three years (dilution for shareholders). It spends 7% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $4M | $5M | $7M | $8M | $10M | $11M | $11M | $12M | $13M | $16M |
| Net income | -$4M | -$3M | -$5M | -$3M | -$4M | -$3M | -$3M | -$21M | -$11M | -$19M | -$9M |
| Free cash flow | — | $88937 | -$444474 | -$711203 | -$811509 | -$687893 | -$909567 | $472309 | $2M | $704737 | $3M |
| EPS (diluted) | $-0.42 | $-0.74 | $-2.71 | $-9.10 | $-37.80 | $-37.00 | $-3.50 | $-24.00 | $-12.50 | $-22.00 | $-10.50 |
| Net margin | -114.3% | -76.9% | -104.6% | -43.9% | -49.0% | -35.3% | -26.4% | -189.5% | -87.2% | -145.9% | -59.0% |
| ROIC | — | -10.5% | -35.1% | -21.5% | -34.5% | -21.7% | -15.3% | -117.9% | -28.1% | -28.2% | -10.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is China Pharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does China Pharma pay a dividend?
Not currently.
Is China Pharma a good stock to buy?
We do not give buy or sell advice. China Pharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.